The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study

Abstract

The cancer genomics field has embraced the advent of precision oncology, and vast volumes of data have been mined for biomarkers of drug actionability. While some cancers have detailed panels of actionable genomic biomarkers, such as lung cancer, breast cancer has been less well-placed to apply standard sequencing panels given its large number of cancer driver genes mutated at a relatively low frequency. Furthermore, mutation signatures have potential to play an important role in the targeting of homologous recommendation deficiency-driven tumours to PARP inhibitor therapy. To investigate whether whole genome sequencing could benefit breast cancer patients we initiated the Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study. We report the analysis of matched tumour and normal genomes of 28 high-risk breast cancer patients, and demonstrate that there are detectable, actionable events that would otherwise have not been identified.